Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Couldnt even liquidate my shares now if I wanted. What happened here? Literally it went from 40-50k shares traded daily to sub 3k. Wtf?
Yeah, disappointing price action/volume. I was hoping after they presented data things would heat but it turned out to be a non-event. I think the issue was that they didn't reveal that much of the data so there was some disappointment. Also, someone said things are progressing slower than had hoped. However, for a stock with a tiny market cap, I think this one could be severely undervalued if they can produce in the near future.
Is this one alive? No volume today and like 10,000 shares the past 3 days.
Bought a starter position in advance to the pending news on results. Hope it's good
FPMI - LifeTech reiterates $2.50PT w/ 2 near -term catalysts
http://lifetechcapital.com/ltc/2014/06/fluoropharma-fpmi-update-06-03-14/
CardioPET PhaseII data to be presented June 7-14th @ the Society of Nuclear Medicine and Molecular Imaging Annual Meeting, June 7-14, in St. Louis, MO
FluoroPharma Medical Announces Presentation of Data From Phase II Clinical Trial of 18F FCPHA (CardioPET) at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting, June 7-14, in St. Louis, MO
8:34 AM ET 5/29/14 | Marketwire
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced that data and analysis from a feasibility study on the quantification of myocardial perfusion in humans by PET/CT utilizing the fatty acid analogue 18F-FCPHA will be presented by the principal investigator, Olivier Gheysens, MD, PhD, at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting.
The study was conducted at the University Hospital Leuven, Belgium. Collaborators on this study include Olivier Gheysens, MD, PhD, Andrey Postnov, PhD, Johan Nuyts, PhD, Koen Van Laere, MD, PhD, DrSc (Department of Nuclear Medicine & Molecular Imaging, University Hospital Leuven, Belgium), Stefan Janssens, MD, PhD (Department of Cardiology, University Hospital Leuven, Belgium) and Manuel Cerqueira, MD (Department of Nuclear Medicine, Cleveland Clinic, Cleveland, Ohio USA.)
B Riley presentation yesterday. 2 upcoming catalysts:
1) Completion of CardioPET phase 2 trial "almost finished"
2) Initiation of BFPET phase 2 trial "any day now"
This company will be bought out before the 5 years is up. I give it ~1 year (or however long it takes to get the phase 2 results back for both products) and it will be at ~$3/share.
What are some price targets people have for the company 5 years from now?
CEO Spoke interview PT 1. http://www.yorba.tv/images/stories/audio/TN040214SEG1.mp3
Any idea what is driving the move today. Volume last 2 days up???
Thanks
New 10K was released today. Been digesting it this morning. Biggest bit of information is regarding BFPET P2 trial. 10K states that "the process for enrollment in this clinical trial has been progressing slowly. We currently expect actual enrollment to commence in the first half of 2014." Not devastating by any means and so far the PPS is holding up ok (down .03 in light trading at 9:50)
Another piece of information is regarding VasoPet: the company is clearly still trying to determine what they are going to do within this "valuable therapeutic area of plaque imaging". They state that, "in light of the limited remaining patent life and our cash constraints, we are not currently allocating resources to this program." Again, not devastating news because we were always mainly focused on CardioPet and BFPET development.
Cash declarations stay consistent with company reiterating that they have enough cash through August '14. The rest of the 10K is quite standard and I will reread it again this evening when I get home from work.
Have a great day everyone!!!
RR
TY for that re-post HMONEY!!! imagine that..a cogent post from yahoo board...who would have thunk it. I like his thought process very much...not sure if I am THAT BULLISH near term...but I like the way he thinks. Another solid day for us here with FPMI; up another 7%. Thats a 50% run of late for those that have been watching this girl stretch her legs!!
Have a great evening everyone!!!
RR
Interesting comment on the yahoo mb by a supposed dr.... take it for what its worth
"Phase II data will be published by the end of the summer
I participated in the recent private placement to fund the balance of the Cardio-Pet Trial and the full BF Pet trial. I recently had dinner with Thijs Spoor while he was in Chicago visiting a few money managers. Two things stand out as key value creators. First, the industry is virtually unknown because imaging agent production is a very closed community. FPMI is the only public company with patents on pipeline drugs. The few producers of SPECT low resolution imaging drugs are divisions of large companies. This is important because the valuations are supported by all players. There is a Japanese Pharmaceutical company currently selling $200 million of the low resolution imaging agent for the SPECT market invented by the same PHD that developed the FPMI high resolution PET imaging agents. This Japanese Pharma company is very interested in adding the Cardio-pet imaging agent to their portfolio of licensed products. They have known about the ongoing development of the Cardio-Pet imaging agent since 2004. It seems probable that a licensing deal of some sort would follow shortly after Phase II data is published in the August time frame.
The industry values both the Cardio-Pet and the BF Pet imaging drugs at $200 million each after Phase II trial data is published. Together, the industry will value the FPMI drugs at $400 million later this year. With a current market cap of only $23 million, FPMI is significantly undervalued. Obviously, the obscurity of this market goes a long way to explain how something could trade at such a discount. Very few people know about FluoroPharma but that is changing rather quickly. The recent appointment of Andrew Sassine to the BOD creates visibility in the right circles. One thing I am quite sure about is that the buying over the last two months has come from people who very much understand the magnitude of the discount to true value of these two imaging drugs. Full value is $12 per share in August. I too am expecting $4 to $6 in 2014."
http://finance.yahoo.com/mbview/threadview/?&bn=92bca517-455f-3995-93fe-78b3187eafe2&tid=1395192826861-f0535638-64fc-498d-b8dd-37a0c9663796&tls=la%2Cd%2C0%2C3
Well our recent trading action clearly sez that is very possible. If this trend continues and then we get a timely and positive PR regarding BFPET data this stock could really move fast.
I'd like to see us close in the mid 70's this week
Nice to be back in the Sheff Station chatter on his IHUB page. He has not stated the he is looking to 're-enter but he has consistently spoken highly of the Flouropharma Mgmt. Team and of course I could not agree more with him. The company really looks to be coming together!!!
Just take a gander at our 5 day chart!!!! I would like our 1 year chart forward to 3/15 to look very similar.
Increased Volume with a steady move higher. Keeping on the pattern of higher highs and higher lows.
Rock On FPMI!!!!
That would certainly be fantastic technically to close EOD at .70+, though longterm its kinda a whatever. loving this increased volume. Not really ceratin what undisclosed news could be creating this action. leaning more towards..the stock is undervalued and slowly more people are taking notice of this companies potential both short and long term. This is not a crowded space and our data has been stellar. And not that there has been any public discussion related to mergers or acquisitions, but in my mind this has always been a contender for a significant partnership or outright acquisition target by a larger player in the healthcare sector looking to take advantage of the future in PET and Flouropharmas pipeline of new imagaing compounds. if the data continues to be solid than this scenario certainly comes more into play, but right now this is nothing but pure speculation on a quiet news day.
Conclusion: The future looks very good for current shareholders.
Thanks Rhodey and it seems like we might hold this 70's area...must be news on the horizon?
Happy St. Pattys Day!!! We have just touched .70 this morning on above average volume. This stock has been on fire!!! Up 40% of late and waiting for BFPET data. Really liking this company's position and pipeline of new imaging agents in the monster imaging sector of healthcare!!!
We are not in need of another round of financing until August so this girl should continue to run Into the summer. I will be adding on any sector weakness and have this as a long-term STRONG BUY!!!!
Have a great day everyone!!!!
RR
I found out about FPMI at the Biotech Showcase in SF in January. Bought 10k shortly after that. Looks like awareness of FPMI is starting to spread.
My initial target is $1...but how high is up?
Absolutely Senderos!!! This historically high volume for Flouropharma is very exciting. Add in a healthy run up over the past 5 trading days and this is beginning to act like a stock that has found significant new interest and is coiled to breakout.
I missed most of the action today, but someone now likes this stock. Glad we were here early.
852K traded, our 2nd largest day ever, with a strong follow thru to yesterdays action...all on a blood red day for the broader markets.... to say that I find this action very bullish would be an understatement.
.655 on strong volume into lunch break!!! Such a strong move from recent lows and well over 30% up from 52 week lows. Really setting up well for a breakout on BFPET P2 Data and updates for advancements into P3 trials for both CardioPET and BFPET (if data is as positive as I expect)!!! These trials for our imaging agent compounds are quite short in duration which is fantastic for us. Having 2 compounds potentially in P3 trials simultaneously is AWESOME!!! Really think that the older SA article I posted earlier presents a clear and plausible scenario of how well Flourophrma is positioned as a leader in the midst of the market transition from SPECT to PET technology.
Again, for me, this is a huge long term play with minimal downside risk (always set your stops for your risk comfort level) and huge upside potential within the Billion Dollar Imaging Space.
Have a great day everyone!!!
RR
Old article on FPMI that some on the board may not have read. http://seekingalpha.com/article/1347781-arm-holdings-biotech-twin-fluoropharma
15 minutes till EOD. Can we hold above .60 on above average volume???? Still a little confused with yesterday's enormous volume, but liking today's action very much right now.
Absolutely!!! Wonder what afternoon volume and action will look like. Be nice if volume and positive trend can continue into BFPET data release. Hoping not only for a positive data release, but information regarding future PIII trials for both CardioPET and BFPET. If everything lines up this girl will certainly test new highs.
I'll be here to find out
Let's see if that big bidder shows up this afternoon.
nice to see .6000's going thru this morning
Something is certainly up. Over 300k above out highest volume day ever With this company. Even though she traded flat for the day, that increase is crazy. Doing some investigative work this AM. Let the board know if anything significant comes to light.
Something would seem to be brewing. Tomorrow should be worth watching.
Volume precedes price
The 5x volume spike today was very interesting.
MM games IMO. 500k of that has already disappeared.
One would hope
964K on the bid at .55! what is that all about? Is this thing is about to blow!
Solid open on 30k volume. Clearly she is volatile and could pull back like yesterday, but she is primed for a breakout on news. BFPET data and company outlook for rest of 2014 is highly anticipated by this motivated investor!!!
Off to work!!!
Have a super day everyone!!!
RR
I find it quite a testament to your online character that you would feel the need to submit such a post. Its a shame really. Not a healthy way to go through the day harboring those negative emotions IMO. I was simply letting you know that I was doing my part to get some action going for you by adding a wee bit to my holdings in this stock.
I have always stated that this is a long term play with large upside potential. Adding at these levels makes perfect sense to me and buying undervalued stocks when few people are excited about it has proven to be a successful strategy for me throughout the years.
As always I wish you and the rest of the board a wonderful evening.
RR
Nice add.....already in the red!
IF69, I added again today at .54. I hope this helps your day a wee bit.
We will get there my friend!!! BFPET data is on the horizon!!!
Have a stellar day!!!
RR
Followers
|
21
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
371
|
Created
|
09/20/10
|
Type
|
Free
|
Moderators |
FluoroPharma Medical, Inc. 8 Hillside Ave Suite 207 Montclair, NJ 07042 Phone: (973) 744-1565 www.FluroPharma.com Info@FluoroPharma.com | MissionIR 3645 Marketplace Blvd. Suite 130-280 Atlanta, GA 30344 Phone: (404) 941-8975 www.MissionIR.com Editor@MissionIR.com |
FluoroPharma Medical, Inc. (FPMI) is focused on discovering and developing patented Positron Emission Tomography (PET) imaging products to improve patient management by evaluating cardiac disease at the cellular and molecular levels. The market growth for this imaging technology presents tremendous opportunity for innovative developments that address unmet medical needs. FluoroPharma is currently advancing four different imaging agents to fulfill these critical needs while providing clinicians important tools for detecting and assessing pathology before critical manifestations of disease.
Unlike traditional imaging modalities (MRI, CT, and Ultrasound) that reveal the anatomical abnormalities and cause for disease, PET provides insight into physiology and can detect disease non-invasively before anatomical manifestation is identified by offering visualization of biological processes at the molecular and cellular level.
Featuring higher resolution scans with only a third of the radiation dose, as well as higher levels of reimbursement, PET has become the preferred imaging technology for a variety of diseases and disorders.
For more information, visit www.FluoroPharma.com
Presentation FPMI.MissionIR.com/Presentation
CardioPET (coronary artery disease) is on track to start Phase IIb clinical trials by year end. This muscle state imaging agent exploits the dietary needs of the heart as it relates to glucose and fatty acids. By introducing a radio-labeled analog to the natural fatty acids utilized as an energy source by the heart, the technology allows for the visualization of the anatomic location and state of the muscle to detect problems in advance of symptoms that would lead to a stress test.
FluoroPharma believes that within the third year of launch, CardioPET could be used in approximately 700k procedures, growing to 1+ million procedures in the following five years. This could equate to a potential revenue opportunity to FluoroPharma of approximately $400 million in the third year (2019/2020) and $600+ million in the fifth year (2021/2022) after launch.
BFPET (coronary artery disease) Phase II clinical trial results are expected by year end. BFPET, a Flourine-18 labeled tracer, has been designed to enter the myocardial cells in direct proportion to blood flow and cell membrane potential. These are two of the most important physiological indicators upon which adequate blood supply to the heart depends. BFPET has been designed to differentiate among those cells of the myocardium that may be ischemic, infarcted and those that are healthy.
FluoroPharma estimates that BFPET could capture about 1% - 3% of the total market for MPI radiopharmaceuticals in the first full year after launch (possibly 2016/2017) and will account for about 20% - 30% of the market five years following launch (possibly 2021/2022). Contingent on the selling price that the Company is able to achieve, this could mean revenue from sales of BFPET as high as $50 million in the first full year after launch and $700 million five years after launch.
*CardioPET could be used in combination with FluoroPharma’s BFPET or other blood flow agents in performing Cardiac Viability Assessment (CVA)
VasoPET (coronary artery disease) is on track for Phase Ib clinical trial by year end. By targeting the active adenosine phosphate molecule receptors which are associated with inflammatory conditions this imaging agent allows us to visualize potential areas that may cause embolisms and thrombosis. VasoPET is designed for patients that have already had a heart attack or stroke with the risk of a potentially fatal recurrence.
FluoroPharma believes that VasoPET could be used in approximately 30k PET scans in the first full year of launch, growing to 450k and 700k scans in the third and fifth year (post-launch), respectively. Assuming a $600 cost per dose, this could result in revenue opportunity of $18 million in year one (2017/2018), $270 million in year three, and $420 million in year five (2022/2023).
AZPET (Alzheimer’s disease) is an imaging agent that attaches to the amyloid deposits (plaque) in the brain and makes them visible on a PET Scan, thus allowing the early detection of Alzheimer’s disease.
According to GAI, the market for molecular imaging agents currently exceeds $1.7 billion annually and promises rapid growth for the foreseeable future - the global market for molecular imaging agents is projected to exceed $15 billion by 2015. With one in three patients dying because of heart disease, FluoroPharma's cardiovascular program addresses the largest segment of the nuclear medicine market.
The World Health Organization estimates that 7.3 million deaths were directly attributable CAD during 2008 (12.8% of all global deaths), making CAD the leading cause of death worldwide. In the United States alone, cardiovascular disease is responsible for 32%, or 1 in every 3 deaths, of all deaths.
FluoroPharma's comprehensive technology platform aims to help the medical community diagnose disease more accurately at the earliest stages, leading to more effective treatment and better patient outcomes.
To date, the company has been issued patents related to its portfolio of imaging compounds in the United States, Europe, China, Japan, Canada, Australia, Finland, Portugal, Ireland, and Mexico. FluoroPharma is backed by a highly experienced management team and the necessary resources to advance clinical development and capitalize on its superior imaging technology.
Novel Cardiac PET Tracing Agents Market Forecast to grow by at least 14% Annually to Approximately $900 million by 2017
FluoroPharma’s products utilize positron emission tomography (PET) technology, a molecular imaging platform that is growing rapidly due to its inherently superior sensitivity and specificity compared to other imaging options. The company’s PET imaging products improve patient management by evaluating cardiac disease at the cellular and molecular levels.
Molecular Imaging Market
Molecular imaging fulfills unmet needs in diagnosis and follow-up therapy by enabling visualization, characterization, and measurement of biological processes at the molecular and cellular level. Unlike more commonly known imaging modalities – MRI, CT, and Ultrasound– that provide insight into the anatomical manifestation of disease, molecular imaging techniques provide insight into physiology and can detect disease before anatomical manifestation is identified.
Cardiovascular Market
Symptomatic coronary artery disease (CAD) affects more than 13 million patients and accounts for more than 30% of all deaths. Cardiologists’ demand for faster, more accurate diagnostic tools continuously drives the development of non-invasive techniques with increased sensitivity and accuracy for the detection and assessment of acute and chronic CAD. Molecular imaging is currently used in more than 9 million myocardial perfusion imaging (MPI) procedures, the standard test for diagnosing CAD.
Additional Diagnostic Markets
Approximately 5.2 million people in the United States are living with Alzheimer’s and 10 million Baby Boomers will develop the disease in their lifetime. Currently, there is no single diagnostic test that proves a person has AD. FluoroPharma is developing new options for early detection and treatment of Alzheimer’s, to improve patient care and create new paths for Alzheimer’s disease management.
Prostate cancer is the most frequently diagnosed and second most lethal malignancy among men in the United States. FluoroPharma is developing new compounds to enable earlier and more accurate diagnosis of prostate cancer.
Following is a list of FluoroPharma’s patents and pending patents:
Cardiovascular and thrombus imaging agents, methods and kits
United States Patent 6,299,857
Elmaleh, et al.
Issued - October 9, 2001
Expires – December 27, 2016
Foreign patents granted: EP, JP, MX, FR, DE, CH, UK
Tumor imaging agents, methods and kits
United States Patent, 6,187,286
Elmaleh, et al.
Issued - February 13, 2001
Expires - December 27, 2016
Foreign patents granted: CA, MX, EP, AU
Imaging Agents for Early Detection and Monitoring of Cardiovascular Plaque
US Patent Pending No. 98 94 5939
Elmaleh, et al.
Utility (CIP): 09/530,818 #7060251
Granted - June 13, 2006
Expires - September 8, 2018
Utility: 11/286,930 #7,438,891
Issued - October 7, 2008
Expires - September 8, 2018
Foreign patents granted: AU DIV
Method for Monitoring Blood Flow and Metabolic Method for Uptake in Tissue with Radiolabeled Alkanoic Acid
Elmaleh et.al.
United States Patent No. 7,790,142 B2
Issued – September 7, 2010
Expires – February 3, 2025.
Foreign patents granted: EP, HK.
Catalytic Radiofluoronation
Elmaleh et. al.
United States Patent No. 7632485
Issued – December 15, 2009
Expires- February 24, 2025
Foreign patents granted: MX
Biotin Compounds for Targeting Tumors and Sites of Infection
Elmaleh et. al.
United States Patent No. 5716594
Issued – February 10, 1998
Expires – June 6, 2014
Foreign patents granted: JP, HK, EP, FR, DE, IE, UK
FluoroPharma has compiled a number of valuable online resources that pertains to the Company’s research. To read the latest industry news, learn about latest advances in molecular imaging diagnostics and therapy and understand emerging imaging technologies please click on any of the links below.
Radiology Links:
Cardiac Imaging Links:
Imaging Molecular Imaging Links:
Thijs Spoor Chairman of the Board, CEO & President
Thijs Spoor holds a Nuclear Pharmacy degree from the University of Toronto as well as an M.B.A. from Columbia University with concentrations in finance and accounting. He has been a guest lecturer at Columbia Business School, Kings College in London, and the University of Newcastle in Australia, and has presented at medical grand rounds and psychiatric grand rounds at various hospitals on the role of brain imaging.
Spoor previously held the title of CFO for Sunstone BioSciences. Prior to joining Sunstone BioSciences, he worked as a consultant at Oliver Wyman where he helped pharmaceutical and medical device companies evaluate their global revenue potential given the complex interplay of regulatory approvals, the reimbursement environment, as well as the impact of physician preference within constantly evolving standards of care. He further specialized on the implications of healthcare reform on new product approval and health insurance reform.
Spoor has also been an equity research analyst at J.P. Morgan and Credit Suisse where he covered the Biotechnology and Medical Device industries. Spoor worked in the pharmaceutical industry spending 10 years with Amersham / GE Healthcare where he worked in seven countries in a variety of roles including setting up GMP facilities meeting ISO 9001 standards, accountability for the entire nuclear cardiology portfolio, and most recently as the Director of New Product Opportunities leading the PET strategic plan.
Boyan Goumnerov, MD COO & Vice President Clinical Trials
Dr. Boyan Goumnerov has held executive positions in the healthcare and biomedical research fields, the most recent being his role as president of VasoStent Inc. and managing director of CardioVas Inc., start-up medical device companies targeting the field of intravascular cardiac imaging and therapy. His academic background includes research within the departments of Surgery and Molecular Biology at the Massachusetts General Hospital (MGH) and The Shriners Burn Hospital for Children, Boston, where he held academic appointments with Harvard Medical School. Dr. Goumnerov also did extensive work within the Department of Pathology/Neuropathology at Children's Hospital Boston, in developing image analysis protocols for evaluation of neuromuscular diseases before moving to MGH. He is co-author of numerous scientific publications. Dr. Goumnerov obtained his M.D. from the Medical University of Sofia, Bulgaria, and worked as a clinician prior to relocating to the United States.
Tamara Rhein CFO
Before joining FluoroPharma in 2011 as Controller, Tamara Rhein was the Controller of Manhattan Pharmaceuticals where she was responsible for maintaining the critical financial functions as well as performing a wide range of activities including financial statement preparation, footnote disclosures for SEC filings, stock option accounting, and quarterly and year-end audits. Prior to Manhattan, Rhein was employed with Vyteris, where her primary role was to manage the SEC accounting and reporting department. In addition to her financial responsibilities, Rhein worked with the CEO on the launch of a new product. In this capacity, she managed critical aspects of coordination, timing, and tracking of the initiative.
Rhein also previously served vice president of New Business at Credit Suisse First Boston, where she provided comprehensive research and analysis to guide senior management on certain projects and complex business transactions; and vice president of External Reporting at Donaldson, Lufkin & Jenrette, where she prepared and reviewed SEC filings for Donaldson, Lufkin & Jenrette as well as Donaldson, Lufkin & Jenrette direct. She was extensively involved in the Initial Public Offering of the Donaldson, Lufkin & Jenrette direct tracking stock issued in May 1999.
Rhein began her career as a senior auditor for Deloitte & Touche, where she planned and administered audit engagements for several large banks and insurance companies. She received a Bachelor of Science in Accounting from California State University, and is a Certified Public Accountant.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |